BiomX Inc has a consensus price target of $3.63 based on the ratings of 4 analysts. The high is $8 issued by Ladenburg Thalmann on May 12, 2022. The low is $2 issued by HC Wainwright & Co. on May 21, 2024. The 3 most-recent analyst ratings were released by Laidlaw & Co., HC Wainwright & Co., and HC Wainwright & Co. on May 28, 2024, May 21, 2024, and April 22, 2024, respectively. With an average price target of $2.17 between Laidlaw & Co., HC Wainwright & Co., and HC Wainwright & Co., there's an implied 673.81% upside for BiomX Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
05/28/2024 | Buy Now | 792.86% | Laidlaw & Co. | Yale Jen | → $2.5 | Initiates | → Buy | Get Alert |
05/21/2024 | Buy Now | 614.29% | HC Wainwright & Co. | Joseph Pantginis | → $2 | Reiterates | Buy → Buy | Get Alert |
04/22/2024 | Buy Now | 614.29% | HC Wainwright & Co. | Joseph Pantginis | → $2 | Reiterates | Buy → Buy | Get Alert |
04/03/2024 | Buy Now | 614.29% | HC Wainwright & Co. | Joseph Pantginis | → $2 | Reiterates | Buy → Buy | Get Alert |
03/07/2024 | Buy Now | 614.29% | HC Wainwright & Co. | Joseph Pantginis | → $2 | Reiterates | Buy → Buy | Get Alert |
11/14/2023 | Buy Now | 2400% | HC Wainwright & Co. | Joseph Pantginis | → $7 | Reiterates | Buy → Buy | Get Alert |
08/09/2023 | Buy Now | 2400% | HC Wainwright & Co. | Joseph Pantginis | → $7 | Reiterates | → Buy | Get Alert |
05/15/2023 | Buy Now | 2400% | HC Wainwright & Co. | Joseph Pantginis | $10 → $7 | Maintains | Buy | Get Alert |
11/10/2022 | Buy Now | 614.29% | Chardan Capital | Keay Nakae | $6 → $2 | Maintains | Buy | Get Alert |
05/24/2022 | Buy Now | 2042.86% | Chardan Capital | Keay Nakae | $10 → $6 | Maintains | Buy | Get Alert |
05/12/2022 | Buy Now | 2757.14% | Ladenburg Thalmann | Michael Higgins | $13 → $8 | Maintains | Buy | Get Alert |
11/16/2021 | Buy Now | 4542.86% | Chardan Capital | Keay Nakae | — | Maintains | Buy | Get Alert |
10/19/2021 | Buy Now | 5614.29% | Chardan Capital | Keay Nakae | — | Maintains | Buy | Get Alert |
10/18/2021 | Buy Now | 3471.43% | HC Wainwright & Co. | Joseph Pantginis | $20 → $10 | Maintains | Buy | Get Alert |
The latest price target for BiomX (AMEX:PHGE) was reported by Laidlaw & Co. on May 28, 2024. The analyst firm set a price target for $2.50 expecting PHGE to rise to within 12 months (a possible 792.86% upside). 7 analyst firms have reported ratings in the last year.
The latest analyst rating for BiomX (AMEX:PHGE) was provided by Laidlaw & Co., and BiomX initiated their buy rating.
There is no last upgrade for BiomX
There is no last downgrade for BiomX.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BiomX, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BiomX was filed on May 28, 2024 so you should expect the next rating to be made available sometime around May 28, 2025.
While ratings are subjective and will change, the latest BiomX (PHGE) rating was a initiated with a price target of $0.00 to $2.50. The current price BiomX (PHGE) is trading at is $0.28, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.